0000899243-23-006296.txt : 20230227 0000899243-23-006296.hdr.sgml : 20230227 20230227205129 ACCESSION NUMBER: 0000899243-23-006296 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230223 FILED AS OF DATE: 20230227 DATE AS OF CHANGE: 20230227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reardon Andrew CENTRAL INDEX KEY: 0001950232 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 23677873 MAIL ADDRESS: STREET 1: C/O LIGAND PHARMACEUTICALS INCORPORATED STREET 2: 3911 SORRENTO VALLEY BLVD, SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-23 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001950232 Reardon Andrew 3911 SORRENTO VALLEY BOULEVARD, SUITE 110 SAN DIEGO CA 92121 0 1 0 0 See Remarks Common Stock 2023-02-23 4 A 0 5668 0.00 A 16608 D Employee Stock Option (right to buy) 75.09 2023-02-23 4 A 0 15393 0.00 A 2033-02-23 Common Stock 15393 15393 D Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on February 15, 2024; February 15, 2025; and February 15, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from February 23, 2023, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after February 23, 2023 and the remaining stock options vesting in 42 equal monthly installments thereafter. Chief Legal Officer and Secretary /s/ Andrew Reardon 2023-02-27